NRF2 as a therapeutic opportunity to impact in the molecular roadmap of ALS

Jiménez-Villegas, J., Ferraiuolo, L. orcid.org/0000-0001-9118-5714, Mead, R.J. orcid.org/0000-0002-3207-0068 et al. (3 more authors) (2021) NRF2 as a therapeutic opportunity to impact in the molecular roadmap of ALS. Free Radical Biology and Medicine, 173. pp. 125-141. ISSN 0891-5849

Abstract

Metadata

Authors/Creators:
Copyright, Publisher and Additional Information: Crown Copyright © 2021 Published by Elsevier Inc. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
Keywords: NRF2; Amyotrophic lateral sclerosis; Therapy; Clinical trials; Dysregulated pathways; Transcriptomic analysis; ALS molecular hallmarks
Dates:
  • Accepted: 15 July 2021
  • Published (online): 24 July 2021
  • Published: September 2021
Institution: The University of Sheffield
Academic Units: The University of Sheffield > Sheffield Teaching Hospitals
Funding Information:
FunderGrant number
Medical Research CouncilMR/S004920/1; MR/V027735/1
Depositing User: Symplectic Sheffield
Date Deposited: 30 Jul 2021 12:58
Last Modified: 30 Jul 2021 12:58
Status: Published
Publisher: Elsevier BV
Refereed: Yes
Identification Number: https://doi.org/10.1016/j.freeradbiomed.2021.07.022

Share / Export

Statistics